^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Steroid receptor agonist

    Related drugs:
    5d
    Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain (clinicaltrials.gov)
    P=N/A, N=954, Not yet recruiting, Beijing Tiantan Hospital
    New trial
    |
    dexamethasone injection
    5d
    Dexamethasone Palmitate for Postoperative Pain (clinicaltrials.gov)
    P=N/A, N=446, Not yet recruiting, Beijing Tiantan Hospital
    New trial
    |
    dexamethasone injection
    6d
    The Effect of Multimodal Pain Regimen on Use of Narcotics After Rotator Cuff Tear Repair (clinicaltrials.gov)
    P4, N=130, Recruiting, Montefiore Medical Center | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    dexamethasone injection
    10d
    Topical Administration of Sitagliptin Prevents Retinal Neurodegeneration in a Model of Glaucoma Induced by Dexamethasone. (PubMed, Int J Mol Sci)
    Glaucoma was induced in mice by periocular injection of dexamethasone (DEX) once weekly for five weeks. Furthermore, it suppressed overexpression of galectin-3 and gamma-synuclein in the optic nerve head (ONH) (p < 0.001), key mediators of inflammation and apoptosis. Sitagliptin eye drops exert a potent neuroprotective effect against corticosteroid-induced glaucoma, supporting their potential as a novel therapeutic strategy for glaucoma.
    Journal
    |
    LGALS3 (Galectin 3)
    |
    dexamethasone injection
    12d
    Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Rutgers, The State University of New Jersey | Trial completion date: Nov 2026 --> Jun 2027 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    abiraterone acetate • prednisone • apalutamide
    12d
    Effect of Dexamethasone on Plasma Levels of Bupivacaine and Dexamethasone After a Single-injection Interscalene Nerve Block. (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, Pontificia Universidad Catolica de Chile
    New trial
    |
    dexamethasone injection
    14d
    NEW-STRAT TB: Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, University of Cape Town | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Jun 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    prednisone
    22d
    Interscalene Block Versus Combined Infraclavicular-Anterior Suprascapular Blocks for Shoulder Surgery (clinicaltrials.gov)
    P=N/A, N=50, Completed, University of Chile | Recruiting --> Completed | Trial completion date: Jun 2026 --> Nov 2025 | Trial primary completion date: Jun 2026 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    dexamethasone injection
    28d
    ANCHOR: Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (clinicaltrials.gov)
    P4, N=1507, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed • HEOR
    1m
    Increased TNF-α in SJS/TEN induced by PD-1 inhibitors supports the combination therapy of etanercept and systemic corticosteroids. (PubMed, Mol Immunol)
    Our findings demonstrated upregulation of TNF-α expression in PD-1 inhibitor-induced SJS/TEN, mainly derived from macrophages. The combination of etanercept and systemic corticosteroids exhibits huge potential for treating this patient population.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    prednisone
    1m
    Long Term of Follow-Up of Melanoma-Associated Retinopathy: A Case Report. (PubMed, Ocul Immunol Inflamm)
    A 48-year-old man with stage IV cutaneousmelanoma with BRAF V600E mutation achieved complete systemic remission with vemurafenib...Sub-Tenon's triamcinolone and intravenous immunoglobulin failed toimprove symptoms, but bilateral intravitreal dexamethasone implants (Ozurdex) resolved visual disturbances and normalized ERG...The absence of autoantibodies and late flares challenges current diagnostic paradigms, emphasizing ERG's critical role. Proactive ophthalmologic surveillance and individualized local therapy canpreserve vision in this underrecognized condition.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Zelboraf (vemurafenib)
    1m
    REAGIR II: Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II (clinicaltrials.gov)
    P3, N=60, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting
    Enrollment closed